dc.contributor.author |
Lamb, LE |
|
dc.contributor.author |
Zhi, X |
|
dc.contributor.author |
Alam, F |
|
dc.contributor.author |
Pyzio, M |
|
dc.contributor.author |
Scudamore, CL |
|
dc.contributor.author |
Wiles, S |
|
dc.contributor.author |
Sriskandan, S |
|
dc.coverage.spatial |
England |
|
dc.date.accessioned |
2021-02-16T21:28:50Z |
|
dc.date.available |
2021-02-16T21:28:50Z |
|
dc.date.issued |
2018-6-19 |
|
dc.identifier.citation |
BMC microbiology 18(1):60 19 Jun 2018 |
|
dc.identifier.issn |
1471-2180 |
|
dc.identifier.uri |
https://hdl.handle.net/2292/54474 |
|
dc.description.abstract |
<h4>Background</h4>The development of vaccines and evaluation of novel treatment strategies for invasive group A streptococcal (iGAS) disease requires suitable models of human infection that can be monitored longitudinally and are preferably non-invasive. Bio-photonic imaging provides an opportunity to reduce use of animals in infection modelling and refine the information that can be obtained, however the range of bioluminescent GAS strains available is limited. In this study we set out to develop bioluminescent iGAS strains for use in in vivo pneumonia and soft tissue disease models.<h4>Results</h4>Using clinical emm1, emm3, and emm89 GAS strains that were transformed with constructs carrying the luxABCDE operon, growth and bioluminescence of transformed strains were characterised in vitro and in vivo. Emm3 and emm89 strains expressed detectable bioluminescence when transformed with a replicating plasmid and light production correlated with viable bacterial counts in vitro, however plasmid instability precluded use in the absence of antimicrobial pressure. Emm89 GAS transformed with an integrating construct demonstrated stable bioluminescence that was maintained in the absence of antibiotics. Bioluminescence of the emm89 strain correlated with viable bacterial counts both in vitro and immediately following infection in vivo. Although bioluminescence conferred a detectable fitness burden to the emm89 strain during soft tissue infection in vivo, it did not prevent dissemination to distant tissues.<h4>Conclusion</h4>Development of stably bioluminescent GAS for use in vitro and in vivo models of infection should facilitate development of novel therapeutics and vaccines while also increasing our understanding of infection progression and transmission routes. |
|
dc.format.medium |
Electronic |
|
dc.language |
eng |
|
dc.publisher |
Springer Science and Business Media LLC |
|
dc.relation.ispartofseries |
BMC microbiology |
|
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
|
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
|
dc.rights.uri |
https://creativecommons.org/licenses/by/4.0/ |
|
dc.subject |
Animals |
|
dc.subject |
Humans |
|
dc.subject |
Mice |
|
dc.subject |
Streptococcus pyogenes |
|
dc.subject |
Streptococcal Infections |
|
dc.subject |
Respiratory Tract Infections |
|
dc.subject |
Disease Models, Animal |
|
dc.subject |
Bacterial Outer Membrane Proteins |
|
dc.subject |
Carrier Proteins |
|
dc.subject |
Luminescent Proteins |
|
dc.subject |
Antigens, Bacterial |
|
dc.subject |
Luminescent Measurements |
|
dc.subject |
Operon |
|
dc.subject |
Female |
|
dc.subject |
Genetic Fitness |
|
dc.subject |
Bioluminescence |
|
dc.subject |
Biophotonic imaging |
|
dc.subject |
Group A Streptococcus |
|
dc.subject |
Infection model |
|
dc.subject |
Invasive disease |
|
dc.subject |
Luciferase |
|
dc.subject |
Streptococcus pyogenes |
|
dc.subject |
Animals |
|
dc.subject |
Antigens, Bacterial |
|
dc.subject |
Bacterial Outer Membrane Proteins |
|
dc.subject |
Carrier Proteins |
|
dc.subject |
Disease Models, Animal |
|
dc.subject |
Female |
|
dc.subject |
Genetic Fitness |
|
dc.subject |
Humans |
|
dc.subject |
Luminescent Measurements |
|
dc.subject |
Luminescent Proteins |
|
dc.subject |
Mice |
|
dc.subject |
Operon |
|
dc.subject |
Respiratory Tract Infections |
|
dc.subject |
Streptococcal Infections |
|
dc.subject |
Streptococcus pyogenes |
|
dc.subject |
Science & Technology |
|
dc.subject |
Life Sciences & Biomedicine |
|
dc.subject |
Microbiology |
|
dc.subject |
Bioluminescence |
|
dc.subject |
Biophotonic imaging |
|
dc.subject |
Group A Streptococcus |
|
dc.subject |
Infection model |
|
dc.subject |
Invasive disease |
|
dc.subject |
Luciferase |
|
dc.subject |
Streptococcus pyogenes |
|
dc.subject |
GALLERIA-MELLONELLA LARVAE |
|
dc.subject |
INFECTION |
|
dc.subject |
PYOGENES |
|
dc.subject |
1108 Medical Microbiology |
|
dc.subject |
Biomedical |
|
dc.subject |
Basic Science |
|
dc.subject |
Emerging Infectious Diseases |
|
dc.subject |
Vaccine Related |
|
dc.subject |
Immunization |
|
dc.subject |
Biodefense |
|
dc.subject |
Infectious Diseases |
|
dc.subject |
Prevention |
|
dc.subject |
Infection |
|
dc.subject |
2.2 Factors relating to physical environment |
|
dc.subject |
2.1 Biological and endogenous factors |
|
dc.subject |
06 Biological Sciences |
|
dc.subject |
07 Agricultural and Veterinary Sciences |
|
dc.subject |
11 Medical and Health Sciences |
|
dc.title |
Modelling invasive group A streptococcal disease using bioluminescence. |
|
dc.type |
Journal Article |
|
dc.identifier.doi |
10.1186/s12866-018-1200-1 |
|
pubs.issue |
1 |
|
pubs.begin-page |
60 |
|
pubs.volume |
18 |
|
dc.date.updated |
2021-01-14T18:56:21Z |
|
dc.rights.holder |
Copyright: The author |
en |
pubs.author-url |
https://www.ncbi.nlm.nih.gov/pubmed/29921240 |
|
pubs.publication-status |
Published |
|
dc.rights.accessrights |
http://purl.org/eprint/accessRights/OpenAccess |
en |
pubs.subtype |
Research Support, Non-U.S. Gov't |
|
pubs.subtype |
research-article |
|
pubs.subtype |
Journal Article |
|
pubs.elements-id |
746122 |
|
dc.identifier.eissn |
1471-2180 |
|
dc.identifier.pii |
10.1186/s12866-018-1200-1 |
|
pubs.number |
60 |
|
pubs.online-publication-date |
2018-6-19 |
|